TD Asset Management
MBX

TD Asset Management’s MBX Biosciences MBX Stock Holding History

TD Asset Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.46M Buy
115,998
+14,548
+14% +$495K ﹤0.01% 860
2025
Q4 		$3.2M Sell
101,450
-17,342
-15% -$421K ﹤0.01% 884
2025
Q3 		$2.08M Sell
118,792
-52,512
-31% -$702K ﹤0.01% 961
2025
Q2 		$1.95M Buy
171,304
+19,800
+13% +$202K ﹤0.01% 947
2025
Q1 		$1.12M Buy
151,504
+114,904
+314% +$1.21M ﹤0.01% 1055
2024
Q4 		$675K Sell
36,600
-8,182
-18% -$174K ﹤0.01% 1150
2024
Q3 		$1.07M Buy
+44,782
New +$1.02M ﹤0.01% 1170

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

TD Asset Management's MBX Position: Q1 2026 in Review

TD Asset Management increased its MBX Biosciences (MBX) stake by 14% in Q1 2026, buying an estimated $495K and bringing the position to 115,998 shares worth $3.46M. The position accounts for ﹤0.01% of the portfolio, ranked #860.

TD Asset Management first reported a position in MBX in Q3 2024 and has held it in 7 quarters since. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • TD Asset Management held 115,998 shares of MBX Biosciences worth $3.46M as of Q1 2026.
  • TD Asset Management bought 14,548 MBX Biosciences shares in Q1 2026, an estimated $495K.
  • MBX Biosciences made up ﹤0.01% of TD Asset Management's portfolio in Q1 2026, its #860 holding.
  • TD Asset Management first reported a position in MBX Biosciences in Q3 2024 and has held it in 7 quarters since.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.